Together,
we can reach higher ground
At Climb Bio, we believe elevating relationships leads to more meaningful insights, better answers, and ultimately, to more inspired medicines for patients living with immune-mediated diseases.
Experienced team
At Climb Bio, our team has a knack for seeing what no one else sees—and a drive to achieve results no one expects.
Elevating possibilities
Our pipeline is focused on immune-mediated diseases, including advancing budoprutug, an anti-CD19 antibody designed for a broad range of B-cell mediated diseases and CLYM116, an anti-APRIL antibody in IND-enabling studies for IgAN.
CANDIDATE
Budoprutug IV
Anti-CD19
Indications
Primary Membranous Nephropathy
Phase 2
Immune Thrombocytopenia
Phase 1
Systemic Lupus Erythematosus
Phase 1
CANDIDATE
Budoprutug SC
Anti-CD19
Indications
Autoimmune Disease
Preclinical
CANDIDATE
CLYM116*
Anti-APRIL
Indications
IgA Nephropathy
Pre-Clinical
Commitment to patients
We only have one life to live. At Climb, we all feel the urgency to give everyone living with an immune-mediated disease more quality time—and less time thinking of themselves as a patient.
Come climb with us
Here you’ll find good people. Smart people. Curious people. Our team has a diversified past, a singular focus on the now, and an unshakeable commitment to a better future.
OPEN POSITIONS: